Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Natural Resource Partners LP reported Q3 2026 results, generating $44.8 million in free cash flow and fully repaying the remaining $13.1 million balance on its credit facility. The company significantly increased its quarterly distribution to $2.34 per common unit, reflecting its progress in de-leveraging the business.
Term
Q3 2026
“NRP generated $45 million of free cash flow in the third quarter of 2026 and $166 million of free cash flow over the last twelve months before accounting for the $39 million investment we made in our soda ash business in the first quarter of 2026.”
Craig Nunez, NRP's president and chief operating officer
“I am delighted that we are nearing the end of our long journey to de-lever and de-risk the business, especially in light of the challenging market environment facing all three of our key commodities.”
Craig Nunez, NRP's president and chief operating officer
Vishay Intertechnology reported record Q3 2026 revenue of $978.9 million, exceeding the top end of its guidance and growing 24% year-over-year. The company achieved a gross margin of 25.5% and diluted EPS of $0.37, driven by strong performance across its semiconductor and passive component technologies under its 'Vishay 3.0' execution strategy.
Term
Q3 2026
“Q3 revenue of $979 million marked the highest quarterly revenue ever in Vishay’s history and exceeded the top end of our guidance. With revenue growth of 24% over last year, we lifted our gross profit margin to 25.5%, 600 basis points higher.”
Joel Smejkal, president and CEO
“We remain intensely focused on execution under Vishay 3.0, delivering on our promise to our customers to be a reliable supplier with incremental capacity and maintain competitive lead times.”
CS Disco reported Q3 2026 total revenue of $45.3 million, an 11% increase year-over-year, and achieved break-even Adjusted EBITDA a quarter ahead of schedule. The company saw 10% growth in software revenue and expanded its large customer base (>$100k ARR) by 15% to 374 customers.
Term
Q3 2026
“DISCO had another strong quarter building AI for Litigators, paced by our sixth consecutive quarter of double-digit software growth, rapid growth in our DISCO Platform, which has grown 10x since Q1 2026, and continued customer enthusiasm for our unified litigation solution which just added a second cohort to our pilot program.”
Eric Friedrichsen, CEO of DISCO
“Importantly, we also reached break-even Adjusted EBITDA in Q3 - a full quarter ahead of schedule.”
Shoals Technologies Group reported a significant increase in revenue to $499.2 million for the nine months ended September 30, 2026, compared to $327.0 million in the prior year period. Net income grew to $29.7 million, though the company experienced a net cash outflow from operating activities of $5.8 million primarily due to increased inventory and accounts receivable levels.
Array Technologies reported Q3 2026 financial results, highlighted by a record orderbook of $2.6 billion, representing a 42% year-over-year increase. The company also announced a definitive agreement to combine with Shoals Technologies Group in a stock-for-stock merger and updated its full-year 2026 revenue guidance to $1.34B-$1.40B.
“The third quarter marked another significant milestone in ARRAY’s evolution from a tracker company to a provider of integrated energy infrastructure solutions. With the completion of our Affordable Wire Management acquisition, we advanced our balance-of-system strategy and gained access to the fast-growing battery energy storage and data center markets.”
Kevin G. Hostetler, Chief Executive Officer
“While our updated full-year guidance reflects shifts in the timing of certain project deliveries, underlying customer demand remains strong and our continued operational execution and cost discipline are driving improved gross margin expectations.”
Kyndryl reported second quarter fiscal 2027 revenue of $3.7 billion and net income of $59 million, reflecting a 1.9% year-over-year revenue decline. The company highlighted strong growth in its hyperscaler-related revenue, which rose 27.2% to over $550 million, and reaffirmed its full-year fiscal 2027 outlook.
“Strong signings and continued growth in Kyndryl Consult and hyperscaler-related revenue reinforce our confidence in our fiscal 2027 outlook. Our performance reflects demand for Kyndryl’s AI-led modernization capabilities and deep mission-critical expertise that help customers evolve their complex technology environments, strengthen cybersecurity and achieve measurable business outcomes.”
Martin Schroeter, Chairman and Chief Executive Officer
“Our results reflect continued progress against our strategic and financial priorities. We remain focused on disciplined execution to strengthen our fundamentals, support margin expansion and drive free cash flow growth.”
Odyssey Therapeutics is a clinical-stage biotechnology company that recently transitioned to a public entity following its IPO. The company reported 48,067,877 shares of common stock outstanding as of November 2, 2026, and continues to incur substantial net losses as it advances its lead product candidates, OD-001 and OD-002, through clinical and preclinical development.
Q32 Bio Inc. reported a net loss of $8.9 million for Q3 2026, with research and development expenses increasing to $5.1 million. The company significantly strengthened its balance sheet during the quarter, ending with $289.6 million in cash and cash equivalents following a $187.5 million follow-on financing and other equity offerings.
Dine Brands Global reported third quarter 2026 financial results, with total revenues increasing to $248.9 million, driven primarily by company-owned restaurant acquisitions. Both Applebee’s and IHOP achieved positive domestic same-restaurant sales growth of 0.9% and 0.8%, respectively, while the company continued to expand its dual-brand restaurant program.
Term
Q3 2026
“This quarter, Applebee’s and IHOP both achieved positive growth due to our everyday value, menu innovation, culturally relevant marketing, and sharper operational execution. We’re focused on supporting the future of our brands, including expanding our dual-brand program, improving our company-owned portfolio, and accelerating our remodel pipeline. We remain confident in the strategy we’ve laid out - building long-term value through consistent execution today and disciplined investment in our future growth.”
John Peyton, Chief Executive Officer of Dine Brands
“Our scale, capital structure and asset-light model continue to generate the financial and strategic flexibility for us to invest across the business while returning capital to our shareholders. We are committed to our disciplined capital allocation priorities with the goal of generating long term shareholder value.”
Vance Chang, Chief Financial Officer of Dine Brands
Lifecore Biomedical reported a significant net loss of $61.2 million for the nine months ended September 30, 2026, compared to a $20.9 million loss in the prior year, primarily driven by a $35.6 million non-cash change in the fair value of a related party debt derivative. Total revenues decreased to $82.7 million from $105.7 million year-over-year, and the company recently entered into a merger agreement with affiliates of Webster Equity Partners.
Lifecore Biomedical reported Q3 2026 financial results, showing a revenue decrease of 18.6% to $25.3 million compared to the prior year. The company reported a net loss of $40.1 million, or $1.08 per diluted share, while highlighting several new business wins in its CDMO pipeline including technology transfer projects and development-phase programs.
Term
Q3 2026
“During the third quarter, Lifecore secured two new technology transfer projects. One will support process performance qualification (PPQ) batches for a biotech company’s new drug application (NDA) for a new chemical entity, and the other will support a currently marketed product for a large pharmaceutical company. We believe these programs will add to Lifecore’s high-value pipeline, and we expect each to contribute to the company’s long-term revenue growth objectives, beginning in 2027”
Paul Josephs, president and chief executive officer of Lifecore
SelectQuote reported first quarter fiscal 2027 revenue of $280.0 million and a net loss of $20.3 million, showing a year-over-year improvement in Adjusted EBITDA and operating cash flow. The company reaffirmed its full-year fiscal 2027 guidance, expecting revenue between $1.35 billion and $1.45 billion and operating cash flow exceeding $60 million.
Term
Q1 2027
“We are proud of another strong quarter across both our Senior and Healthcare Services segments, resulting in a material year-over-year improvement in adjusted EBITDA and operating cash flow. We have high confidence in our current and long-term strategy to drive value for stakeholders, and we are pleased to reiterate our full-year financial targets for fiscal 2027.”
Tim Danker, SelectQuote’s Chief Executive Officer
“SelectQuote’s performance, in our seasonally slowest quarter, showcases the continued impact of our strategy to optimize profitability and cash flow. Despite lower revenue across both Senior and Healthcare Services, SelectQuote drove a 30% improvement in our year-over-year trailing twelve month adjusted EBITDA, and we remain on track to drive over $60 million in operating cash flow in fiscal 2027.”
Fiserv Inc. reported a significant net loss of $5.94 billion for the third quarter of 2026, primarily driven by a $6.45 billion non-cash goodwill impairment charge. Total revenue for the quarter decreased slightly to $5.20 billion compared to $5.26 billion in the prior year period, while operating cash flow for the first nine months of the year remained positive at $3.09 billion.
Rapport Therapeutics reported third quarter 2026 financial results and highlighted positive Phase 2 topline results for RAP-219 in bipolar mania. The company is well-capitalized with $815.4 million in cash following a recent financing, providing a projected runway through the end of 2029.
Term
Q3 2026
“Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company. RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets.”
Abraham N. Ceesay, chief executive officer of Rapport
Geron Corporation reported third quarter 2026 financial results, highlighted by $60.1 million in RYTELO net product revenue, a 5% increase over the prior quarter. The company reiterated its full-year RYTELO revenue guidance at the mid-to-high end of $220-$240 million and initiated a gated commercial launch in Europe, with availability expected in Germany by year-end.
Term
Q3 2026
“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.”
Harout Semerjian, President and Chief Executive Officer of Geron
Viridian Therapeutics reported third quarter 2026 financial results, highlighted by $24.7 million in net product revenue from the launch of Lumvoa (veligrotug-vvze). The company remains on track for a BLA submission for elegrobart in Q1 2027 and expects Phase 1 data for VRDN-008 in Q4 2026.
“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations. These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.”
Steve Mahoney, President and Chief Executive Officer
Datadog reported third quarter 2026 revenue of $1.20 billion, representing 35% year-over-year growth. The company achieved a non-GAAP operating margin of 28% and generated $251 million in free cash flow while expanding its large customer base to 4,860 clients with over $100k in ARR.
Term
Q3 2026
“Datadog delivered a strong third quarter, with 35% year-over-year revenue growth, $290 million in operating cash flow, and $251 million in free cash flow.”
Olivier Pomel, co-founder and CEO of Datadog
“We are innovating rapidly, including developing specialized AI models through our AI Research team, to help customers manage growing complexity and move towards autonomous operations.”
Shoals Technologies Group reported Q3 2026 revenue of $195.3 million, a 43.8% increase year-over-year, driven by strong demand and market share capture. The company reported net income of $17.9 million and raised its full-year 2026 outlook following strong operational performance and the completion of its manufacturing facility transition.
Term
3 months
“We’re very pleased with our strong results in the period, as productivity improvements drove both quarterly revenue and Adjusted EBITDA above our expected range. We remain focused on making meaningful operational improvements as we finish 2026 on a strong note. The long-term health of the market remains robust and we’re well positioned to continue the momentum into 2027 and beyond.”
Brandon Moss, CEO of Shoals
“Our strategy is working — and the results prove it. With the move into our new facility complete, our focus today is on the customer; delivering quality solutions, on time, with market-leading customer service. With an unmatched market position, world-class manufacturing, and a breakthrough innovation pipeline, we are built for what's ahead and excited about the opportunities in front of us.”
uniQure reported Q3 2026 financial results, highlighting a cash position of $768.4 million which is expected to fund operations into 2030. The company also announced that the FDA has granted Priority Review for its BLA for AMT-130 in Huntington’s disease with a PDUFA date of May 1, 2027.
“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease. We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”
Matthew Kapusta, chief executive officer at uniQure
“As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans.”
Matthew Kapusta, chief executive officer at uniQure
Pharmaceutical Resource Technology, Inc. reported a net profit of $132,975 for the nine-month period ended September 30, 2026, on revenues of $8.89 million. The company maintains a strong liquidity position with $5.15 million in cash and concluded that there is no substantial doubt regarding its ability to continue as a going concern.
RYTHM, Inc. reported a significant revenue increase to $60.2 million for the nine months ended September 30, 2026, compared to $6.6 million in the prior year, primarily driven by related party transactions. The company achieved a net income of $20.6 million for the period, largely due to a $26.8 million non-cash income tax benefit from the release of a valuation allowance.
Worksport Ltd. has signed a term sheet for its first-ever acquisition, targeting a patented, U.S.-manufactured truck bed accessory business and its IP portfolio. The company plans to leverage its existing West Seneca manufacturing facility and distribution network to cross-sell and bundle the new product with its tonneau covers.
MoonLake Immunotherapeutics reported Q3 2026 financial results and announced the submission of a Biologics License Application (BLA) to the FDA for sonelokimab in hidradenitis suppurativa. The company ended the quarter with $498.5 million in cash and equivalents, providing a projected cash runway into mid-2028.
CDW Corporation reported third quarter 2026 financial results with net sales of $6.75 billion, a 17.7% increase year-over-year, driven by strong enterprise AI adoption and broad-based customer demand. The company also declared a quarterly cash dividend of $0.680 per share, payable on December 10, 2026.
“CDW delivered robust third quarter results, powered by broad-based strength across our diverse customer end-markets and strong momentum in enterprise AI adoption.”
Christine A. Leahy, chair and chief executive officer, CDW
“Strong customer demand and disciplined execution drove double-digit growth in gross profit, while operating leverage and capital management contributed to more than 20 percent growth in non-GAAP net income per diluted share.”
Nuvectis Pharma reported third quarter 2026 financial results and provided a corporate update following its transformational in-licensing of ex-China rights to NXP100 and NXP200. The company ended the quarter with approximately $140 million in cash, providing a projected runway into the second half of 2029. Management is currently in discussions with the FDA regarding the U.S. regulatory path for ciprocopan (NXP100) in PNH and expects to provide an update by year-end.
“The last few months have been truly transformational for Nuvectis. The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes Nuvectis as a late-stage clinical development company with potential best-in-class assets.”
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
“With its potential for a clear dosing convenience compared to injectable treatments and Fabhalta—the twice-daily oral CFBi—and supported by robust clinical data in PNH and IgAN as well as validating clinical data from the Fabhalta clinical trials, we believe ciprocopan has the potential to redefine the standard of care for patients in targeted settings.”
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
RYTHM, Inc. reported third quarter 2026 revenue of $23.9 million, a 4% sequential increase, and a net loss of $0.5 million. The company highlighted significant growth in its THC beverage portfolio, reaching an annualized run rate of 320,000 cases and expanding retail availability to 8,000 doors across 18 states.
CPI Card Group reported net income of $5.0 million for the third quarter of 2026, more than doubling the $2.3 million reported in the prior year period, driven by a 14.8% increase in revenue to $158.4 million. The company implemented a new segment structure in 2026, separating its proprietary technological solutions into a new Integrated Paytech segment following the acquisition of an on-premise instant issuance solution.
Criteo S.A. reported third quarter 2026 financial results with revenue of $416 million and net income of $6 million. The company highlighted the expansion of its Performance Connected TV capabilities into global markets and its ongoing advertising technology partnership with OpenAI.
“Despite near-term headwinds, we are making tangible progress across our business, with momentum in newer channels and a growing pipeline of opportunities. As we sharpen execution and operate with greater discipline, we remain focused on capturing the opportunities ahead and creating sustainable value for our shareholders.”
Michael Komasinski, Chief Executive Officer of Criteo
Seres Therapeutics reported Q3 2026 financial results and announced plans to advance SER-155 into a study for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC). The company expects to submit the study design to the FDA in Q1 2027 following positive investigator-sponsored trial results showing an 80% clinical response rate.
Term
Q3 2026
“The irEC IST provided promising evidence that orally administered SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with ICI-induced enterocolitis.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
“We believe SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment.”
Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
For the nine months ended September 30, 2026, Brink's reported revenues of $4,142.0 million, a 6.7% increase over the prior year, though net income attributable to the company decreased from $131.6 million to $91.0 million. The company experienced higher operating costs and a significant $62.4 million cash derecognition following the deconsolidation of its Malaysia business.